End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
56.26 CNY | +2.81% | -2.04% | +14.47% |
May. 13 | Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug | MT |
May. 13 | Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.33% | 13.5B | C+ | ||
+29.98% | 682B | C+ | ||
+32.39% | 586B | B | ||
-3.52% | 364B | C+ | ||
+18.59% | 327B | B- | ||
+4.07% | 285B | C+ | ||
+16.50% | 240B | B+ | ||
+9.56% | 209B | B- | ||
-9.04% | 203B | A+ | ||
+7.09% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000538 Stock
- Ratings Yunnan Baiyao Group Co.,Ltd